UnknownPhase 2

Continuous IntraVenous Infusion of Ketamine in Terminally Ill Cancer Patients

South Korea26 participantsStarted 2018-06-01

Plain-language summary

To establish the role of ketamine in hospitalized terminally ill cancer patients with refractory cancer pain, using continuous intravenous infusion of ketamine

Who can participate

Age range18 Years

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Among patients with histologically or cytologically confirmed malignancy, patients with expected survival time of several months or less due to a progressive disease without additional anticancer treatment.
✓. Patients with refractory cancer pain, which cases of requesting 4 or more breakthrough analgesics or increase of baseline analgesics (average pain score ≥ 4 or Personalized pain goal) in spite of 120 mg/day or more of intravenous Morphine Equivalent Daily Dose
✓. Hospitalized patients with intravascular access during at least 5 days
✓. Age 18 or older
✓. Signed and dated informed consent of document indicating that the patient (or legally acceptable representative) has been informed about all pertinent aspects of the trial prior to enrollment

Exclusion criteria

✕. Patients who were treated with ketamine for pain control within 6 months
✕. Patients who have been treated with radiotherapy within 4 weeks or plan to intervention for pain control during study period
✕. Cancer pain cannot be excluded the Opioid induced hyperalgesia
✕. Concomitant severe medical, surgical, or disease or problems which were contraindicated to application of Ketamine or have possibilities of unexpected medical problems caused be the Ketamine

What they're measuring

Overall response rate

Timeframe: From date of enrollment until 5 days or drop-out, assess up to 2 years

Trial details

NCT IDNCT03362073

SponsorPusan National University Yangsan Hospital

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2021-12-31

Contact for this trial

Kwonoh Park, MD, PhD

+82-10-3378-3529 parkkoh@daum.net

View on ClinicalTrials.gov More Ketamine trials